|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagaiah G, Hossain A, Mooney CJ,
Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis, and treatment. J Oncol.
2011:5423582011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Neill JP and Shaha AR: Anaplastic
thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qi Q, Lu N, Wang XT, Gu HY, Yang Y, Liu W,
Li C, You QD and Guo QL: Anti-invasive effect of gambogic acid in
MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol.
86:386–395. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li C, Qi Q, Lu N, Dai Q, Li F, Wang X, You
Q and Guo Q: Gambogic acid promotes apoptosis and resistance to
metastatic potential in MDA-MB-231 human breast carcinoma cells.
Biochem Cell Biol. 90:718–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li D, Song XY, Yue QX, Cui YJ, Liu M, Feng
LX, Wu WY, Jiang BH, Yang M, Qu XB, et al: Proteomic and
bioinformatic analyses of possible target-related proteins of
gambogic acid in human breast carcinoma MDA-MB-231 cells. Chin J
Nat Med. 13:41–51. 2015.PubMed/NCBI
|
|
7
|
Wang S, Wang L, Chen M and Wang Y:
Gambogic acid sensitizes resistant breast cancer cells to
doxorubicin through inhibiting P-glycoprotein and suppressing
survivin expression. Chem Biol Interact. 235:76–84. 2015.
View Article : Google Scholar
|
|
8
|
Wang X, Deng R, Lu Y, Xu Q, Yan M, Ye D
and Chen W: Gambogic acid as a non-competitive inhibitor of
ATP-binding cassette transporter B1 reverses the multidrug
resistance of human epithelial cancers by promoting ATP-binding
cassette transporter B1 protein degradation. Basic Clin Pharmacol
Toxicol. 112:25–33. 2013. View Article : Google Scholar
|
|
9
|
Wang J and Yuan Z: Gambogic acid
sensitizes ovarian cancer cells to doxorubicin through ROS-mediated
apoptosis. Cell Biochem Biophys. 67:199–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Zhou H, Yu Y, Li J, Li H, Jiang
D, Chen Z, Yang D, Xu Z and Yu Z: Combination of gambogic acid with
cisplatin enhances the antitumor effects on cisplatin-resistant
lung cancer cells by downregulating MRP2 and LRP expression. Onco
Targets Ther. 9:3359–3368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu WY, Wu XU, Liao CQ, Shen J and Li J:
Apoptotic effect of gambogic acid in esophageal squamous cell
carcinoma cells via suppression of the NF-κB pathway. Oncol Lett.
11:3681–3685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Z, He N and Zhou Q: Brd4 recruits
P-TEFb to chromosomes at late mitosis to promote G1 gene
expression and cell cycle progression. Mol Cell Biol. 28:967–976.
2008. View Article : Google Scholar
|
|
13
|
Wang YH, Sui YN, Yan K, Wang LS, Wang F
and Zhou JH: BRD4 promotes pancreatic ductal adenocarcinoma cell
proliferation and enhances gemcitabine resistance. Oncol Rep.
33:1699–1706. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang YH, Sui XM, Sui YN, Zhu QW, Yan K,
Wang LS, Wang F and Zhou JH: BRD4 induces cell migration and
invasion in HCC cells through MMP-2 and MMP-9 activation mediated
by the Sonic hedgehog signaling pathway. Oncol Lett. 10:2227–2232.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Segura MF, Fontanals-Cirera B,
Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez
P, Morante M, Jubierre L, Zhang W, et al: BRD4 sustains melanoma
proliferation and represents a new target for epigenetic therapy.
Cancer Res. 73:6264–6276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Puissant A, Frumm SM, Alexe G, Bassil CF,
Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P,
et al: Targeting MYCN in neuroblastoma by BET bromodomain
inhibition. Cancer Discov. 3:308–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce
LA, Thompson RC, Muller S, Knapp S and Wang J: Inhibition of BET
bromodomain targets genetically diverse glioblastoma. Clin Cancer
Res. 19:1748–1759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel AJ, Liao CP, Chen Z, Liu C, Wang Y
and Le LQ: BET bromodomain inhibition triggers apoptosis of
NF1-associated malignant peripheral nerve sheath tumors through Bim
induction. Cell Rep. 6:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J,
Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM: BET
bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lockwood WW, Zejnullahu K, Bradner JE and
Varmus H: Sensitivity of human lung adenocarcinoma cell lines to
targeted inhibition of BET epigenetic signaling proteins. Proc Natl
Acad Sci USA. 109:19408–19413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andrieu G, Tran AH, Strissel KJ and Denis
GV: BRD4 regulates breast cancer dissemination through
Jagged1/Notch1 signaling. Cancer Res. 76:6555–6567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Molinaro E, Romei C, Biagini A, Sabini E,
Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini
A, Torregrossa L, et al: Anaplastic thyroid carcinoma: From
clinicopathology to genetics and advanced therapies. Nat Rev
Endocrinol. 13:644–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔC T method. Methods. 25:402–408.
2001. View Article : Google Scholar
|
|
24
|
Gao X, Wu X, Zhang X, Hua W and Zhang Y,
Maimaiti Y, Gao Z and Zhang Y: Inhibition of BRD4 suppresses tumor
growth and enhances iodine uptake in thyroid cancer. Biochem
Biophys Res Commun. 469:679–685. 2016. View Article : Google Scholar
|
|
25
|
Mio C, Lavarone E, Conzatti K, Baldan F,
Toffoletto B, Puppin C, Filetti S, Durante C, Russo D, Orlacchio A,
et al: MCM5 as a target of BET inhibitors in thyroid cancer cells.
Endocr Relat Cancer. 23:335–347. 2016. View Article : Google Scholar : PubMed/NCBI
|
